{"entity":{"id":"nct07617493","kind":"trial","name":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of ICP-B208 in advanced solid tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","summary":"Evaluation of ICP-B208 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07617493 by Beijing InnoCare Pharma Tech Co., Ltd., with 539 participants planned, started 2026-07-03 and due to reach its primary completion in 2030-12. Interventions recorded: ICP-B208.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07617493","url":"https://clinicaltrials.gov/study/NCT07617493"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07617493","phase":"1/2","setting":"An Open, Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Efficacy of ICP-B208 in Participants of Advanced Solid Tumor Trials","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","enrolled":539,"outcomes":[]},"route":"/trials/nct07617493/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}